Enjoy complimentary customisation on priority with our Enterprise License!
Report on How AI is Driving Market Transformation 
The exosome therapeutics market size is forecast to increase by USD 234.7 million at a CAGR of 16.19% between 2023 and 2028. The market is experiencing significant growth, driven by the increasing prevalence of chronic diseases and the advanced technology in exosome collection. The therapeutic potential of exosomes, which are small extracellular vesicles, has gained increasing attention due to their ability to carry bioactive molecules that can influence cellular functions. The market is also influenced by strict regulatory approval processes for exosome therapeutics launches, ensuring the safety and efficacy of these innovative treatments. As research progresses and technology advances, the use of exosomes in therapeutics is expected to expand, offering new opportunities for the development of effective treatments for various diseases.
Exosomes, a type of extracellular vesicles (ECVs), have gained significant attention in the scientific community due to their potential role in various therapeutic and diagnostic applications. These natural nanovesicles, derived from various cellular sources such as mesenchymal stem cells, dendritic cells, and other body fluids including blood, urine, saliva, milk, and others, carry bioactive molecules that can influence cellular communication and function. Exosome-based therapeutics represent a burgeoning field in personalized medicine, offering potential solutions for chronic diseases, infectious diseases, autoimmune diseases, and cancer. These therapeutics can be derived from natural exosomes or engineered through hybrid methods, allowing for the manipulation of their cargo for enhanced therapeutic efficacy.
Moreover, the isolation, characterization, and analysis of exosomes have become crucial aspects of exosome research. Advanced technologies such as scale-X fixed-bed bioreactors facilitate the large-scale production of exosomes, ensuring their consistent quality and purity. Exosome analysis techniques, including molecular diagnosis, enable the identification of specific biomarkers, providing valuable insights into disease progression and response to treatment. Exosome therapeutics hold great promise in the field of immunotherapy and chemotherapy. For instance, exosomes derived from dendritic cells can be used to stimulate the immune system, enhancing the body's ability to fight infections and cancer. Similarly, exosomes from mesenchymal stem cells can be employed for their regenerative properties, aiding in tissue repair and regeneration.
Furthermore, the diagnostic market for exosomes is also experiencing growth, with potential applications in the early detection and monitoring of various diseases. Exosomes carry disease-specific biomarkers, making them ideal candidates for molecular diagnostics. FDA approvals for exosome-based diagnostic tests are expected to accelerate the market's growth in the coming years. Gene therapies and cell-based therapies are other areas where exosomes play a crucial role. Exosomes can be engineered to deliver therapeutic genes or proteins to specific cells, bypassing the need for viral vectors and minimizing potential side effects. Additionally, exosomes can be used to enhance the efficacy of cell-based therapies by facilitating cell-cell communication and improving cell survival.
In conclusion, exosome therapeutics represent a promising frontier in medicine, offering potential solutions for various diseases and diagnostic applications. The advancements in exosome isolation, characterization, and analysis techniques, along with the growing interest in personalized medicine, are expected to drive the growth of the market in the coming years.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The cancer therapies segment is estimated to witness significant growth during the forecast period. Exosomes, small vesicles released by cells, have emerged as a promising therapeutic modality in various medical fields, including gene therapy, oncology, cardiac disorders, neurology, inflammatory disorders, organ transplantation, gynecology disorders, and blood disorders. Exosomes' transporting capacity for biomacromolecules and small molecules makes them ideal candidates for delivering therapeutic agents to specific cells or tissues. In cancer therapy, engineered exosomes can be utilized to transport chemotherapeutic agents or nucleic acids directly to tumor sites, thereby enhancing the therapeutic effects of anti-cancer medications and minimizing side effects. This targeted drug delivery approach holds immense potential for improving treatment efficacy and reducing the overall burden of conventional therapies.
Get a glance at the market share of various segments Request Free Sample
The cancer therapies segment was valued at USD 63.00 million in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 30% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The North American market is poised for substantial expansion over the coming years. With a substantial investment in healthcare, the region's expenditure reached approximately USD 4.8 trillion in 2023. This increasing healthcare budget in North America offers a favorable environment for the growth of the market. The region's emphasis on healthcare innovation and advanced therapies fuels the demand for exosome-based treatments, thereby driving market expansion. Key factors propelling the market growth include the rising number of cancer cases, the growing adoption of advanced diagnostic tests like liquid biopsy kits, an aging population, substantial spending on cancer screening, and the burgeoning number of biotechnology and pharmaceutical companies spearheading the development of novel cancer treatments. In addition, exosomes derived from blood plasma have emerged as valuable diagnostic biomarkers for various chronic diseases, infectious diseases, autoimmune diseases, and cancers. Clinical trials for exosome therapeutics are underway, presenting significant opportunities for market growth.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increasing prevalence of chronic diseases is the key driver of the market. Exosome technology, derived from cells, is gaining significant attention in the pharmaceutical and biopharmaceutical sectors for its potential application in drug development for chronic diseases. Chronic conditions, such as neurodegenerative diseases like Alzheimer's and Parkinson's, cardiovascular dysfunction, and breast cancer, affect millions worldwide. Exosomes, with their multifunctional properties, offer a promising solution for delivering drugs directly to the affected areas. For instance, in the context of neurodegenerative diseases, exosomes can penetrate the blood-brain barrier, making them an ideal candidate for treating conditions like Alzheimer's and Parkinson's. In the realm of cardiovascular dysfunction, exosomes can aid in the repair of damaged heart tissue in chronic heart failure.
In the field of precision medicine, exosomes' unique properties make them a valuable tool for targeted drug therapies. As per recent studies, exosomes can encapsulate drugs and deliver them to specific cells, minimizing the risk of side effects and increasing the efficacy of treatments. The potential of exosome therapeutics is vast, and ongoing research is expected to yield significant advancements in the near future.
Advanced technology in exosome collection is the upcoming trend in the market. The market is experiencing significant advancements due to innovative technologies in exosome collection. These technologies facilitate more efficient and productive exosome isolation and analysis from intricate biological specimens. Microfluidic devices, immunoaffinity capture, and continuous-flow systems are some of the new technologies leading to the enrichment of exosomes, enabling further downstream applications in therapeutics. Microfluidic devices, in particular, provide high-capacity, streamlined methods for exosome separation using techniques like deterministic lateral displacement and integrated immune isolation. Advanced technologies in exosome collection enable precise manipulation of small fluid volumes through microchannels with dimensions ranging from tens to hundreds of micrometers.
Strict regulatory approval for exosome therapeutics launches is a key challenge affecting the market growth. Exosome therapy, which utilizes nanosized particles derived from cells to transport genetic and protein cargo, holds significant promise in the treatment of various cancers, including prostate, liver, and lung. Aethlon Medical is one of the leading companies in this field. However, gaining regulatory approval for exosome therapeutics is a complex process. Good manufacturing practices (GMP) must be strictly adhered to during the production of exosomes in clinical trials. The upstream cell cultivation process and downstream purification process, as well as exosome quality control, are crucial aspects of GMP. companies must comply with regulatory requirements for manufacturing processes and ensure the safety and efficacy of their products during clinical proof-of-concept.
These regulatory hurdles can significantly delay the commercialization of exosome therapeutics, primarily impacting marketing approval and manufacturing. In the US, the VA Healthcare system and various instruments and software companies are exploring the potential of exosome therapy in liquid biopsy tests, such as the ExoDx Prostate test. This trend is expected to drive the growth of the market in North America.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Aegle Therapeutics - The company offers exosome therapeutics products such as AGLE-102TM- EV Therapy and others.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Exosome therapeutics refer to the use of exosomes, which are natural nanovesicles released by various cell types, for therapeutic applications. Exosomes derived from various sources such as mesenchymal stem cells, dendritic cells, and blood, can carry biomacromolecules, including proteins and genetic cargo, making them promising candidates for immunotherapy, chemotherapy, and gene therapy. Exosomes can be isolated from body fluids like urine, saliva, milk, and blood plasma using techniques such as ultracentrifugation, precipitation, chromatography, and immunoaffinity capture. Exosome-based therapeutics hold significant potential in the diagnosis and treatment of various chronic and acute diseases, including metabolic disorders, oncology, cardiac disorders, neurology, inflammatory disorders, organ transplantation, gynecology disorders, and blood disorders.
However, the therapeutic market for exosomes is expected to grow significantly due to the multifunctional properties of these nanovesicles in drug development and delivery. Exosome diagnostics market is also gaining traction due to their potential as diagnostic biomarkers for various diseases. Liquid biopsy kits and exosome isolation, characterization, and analysis tools are being developed to facilitate the use of exosomes in molecular diagnosis. The FDA has approved several exosome-based therapies and gene therapies, paving the way for their commercialization. The healthcare infrastructure, including hospitals and diagnostic centers, is investing in exosome technology to improve patient care and outcomes. Exosomes have a transporting capacity for small molecules and can be used for parenteral and oral administration.
Moreover, their use in personalized medicine and precision medicine is also being explored to develop targeted therapies for cancer, infectious diseases, autoimmune diseases, and neurodegenerative disorders. The development and production of exosomes are also gaining attention in the pharmaceutical and biopharmaceutical industries due to their potential in drug therapies and drug development.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
202 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 16.19% |
|
Market growth 2024-2028 |
USD 234.7 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
15.76 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 30% |
|
Key countries |
US, Germany, UK, China, and Japan |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Aegle Therapeutics, Aethlon Medical Inc., AMS Biotechnology Europe Ltd., Bio Techne Corp., Capital Biosciences Inc., Capricor Therapeutics Inc., CILOA SAS, Creative Biolabs, Cytiva, Everzom, Evotec SE, Evox Therapeutics Ltd., ExoCoBio Co. Ltd., Inoviq Ltd., Lonza Group Ltd., NanoFCM Co., Ltd, Regeneron Pharmaceuticals Inc., ReNeuron Group plc, The ExoBiologics Co., and Thermo Fisher Scientific Inc. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Technavio Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Application
9 Market Segmentation by Distribution Channel
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
With the growing adoption of AI across industries, Technavio has analyzed its impact on the exosome therapeutics market driven by the integration of Artificial Intelligence (AI). AI is advancing this rapidly growing field by optimizing drug delivery systems, speeding up therapeutic discovery, improving diagnostic accuracy, and personalizing treatment regimens. These insights, available exclusively through Technavio, provide an unparalleled significant impact of AI on the exosome therapeutic market, backed by real-world examples and data.
The report provides details of AI's impact on various segment
Learn more about how AI is transforming the Exosome Therapeutic Market - Buy Full Report Now
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
